Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | Zendy

Gabriel N. Hortobágyi | Zendy; Salomon M. Stemmer | Zendy; Howard A. Burris | Zendy; Yoon Sim Yap | Zendy; Gabe S. Sonke | Zendy; Shani PaluchShimon | Zendy; Mario Campone | Zendy; Kimberly Blackwell | Zendy; Fabrice André | Zendy; Eric P. Winer | Zendy; Wolfgang Janni | Zendy; Sunil Verma | Zendy; Pierfranco Conté | Zendy; Carlos L. Arteaga | Zendy; David Cameron | Zendy; Katarína Petráková | Zendy; Lowell L. Hart | Zendy; Cristian Villanueva | Zendy; Arlene Chan | Zendy; Erik Jakobsen | Zendy; Arnd Nusch | Zendy; Olga Burdaeva | Zendy; EvaMaria Grischke | Zendy; Emilio Alba | Zendy; Erik Wist | Zendy; Norbert Marschner | Zendy; Anne Favret | Zendy; Denise A. Yardley | Zendy; Thomas Bachelot | Zendy; Ling-Ming Tseng | Zendy; Sibel Blau | Zendy; Fengjuan Xuan | Zendy; Farida Souami | Zendy; Michelle C. Miller | Zendy; Caroline Germa | Zendy; Samit Hirawat | Zendy; Joyce O’Shaughnessy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Author(s) -

Gabriel N. Hortobágyi,

Salomon M. Stemmer,

Howard A. Burris,

Yoon Sim Yap,

Gabe S. Sonke,

Shani PaluchShimon,

Mario Campone,

Kimberly Blackwell,

Fabrice André,

Eric P. Winer,

Wolfgang Janni,

Sunil Verma,

Pierfranco Conté,

Carlos L. Arteaga,

David Cameron,

Katarína Petráková,

Lowell L. Hart,

Cristian Villanueva,

Arlene Chan,

Erik Jakobsen,

Arnd Nusch,

Olga Burdaeva,

EvaMaria Grischke,

Emilio Alba,

Erik Wist,

Norbert Marschner,

Anne Favret,

Denise A. Yardley,

Thomas Bachelot,

Ling-Ming Tseng,

Sibel Blau,

Fengjuan Xuan,

Farida Souami,

Michelle C. Miller,

Caroline Germa,

Samit Hirawat,

Joyce O’Shaughnessy

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1609709

Subject(s) - medicine , hazard ratio , breast cancer , letrozole , palbociclib , progression free survival , oncology , metastatic breast cancer , clinical endpoint , interim analysis , placebo , cancer , confidence interval , surgery , randomized controlled trial , tamoxifen , chemotherapy , pathology , alternative medicine

The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research